Search Results

There are 2828 results for: content related to: Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy

    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12616

  3. Anti-IgE in Persistent Severe Allergic Asthma

    Allergy and Allergic Diseases, Volume 1, Second Edition

    Marc Humbert, Stephen T. Holgate, Howard Fox, Jean Bousquet, Pages: 1661–1686, 2009

    Published Online : 10 FEB 2009, DOI: 10.1002/9781444300918.ch81

  4. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 37, Issue 4, April 2017, Pages: 464–480, Alessandro Tonacci, Lucia Billeci, Giovanni Pioggia, Michele Navarra and Sebastiano Gangemi

    Version of Record online : 23 MAR 2017, DOI: 10.1002/phar.1915

  5. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  6. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Version of Record online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  7. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Version of Record online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  8. You have free access to this content
    Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue S5, July 2016, Pages: 25–32, A. M. Giménez-Arnau, E. Toubi, A. M. Marsland and M. Maurer

    Version of Record online : 10 JUN 2016, DOI: 10.1111/jdv.13697

  9. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Version of Record online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  10. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment

    British Journal of Dermatology

    Volume 173, Issue 2, August 2015, Pages: 404–415, M.C. Urgert, M.T. van den Elzen, A.C. Knulst, Z. Fedorowicz and E.J. van Zuuren

    Version of Record online : 22 JUL 2015, DOI: 10.1111/bjd.13845

  11. You have free access to this content
    Management and treatment of chronic urticaria (CU)

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue S3, June 2015, Pages: 16–32, M. Maurer, M.K. Church, M. Gonçalo, G. Sussman and M. Sánchez-Borges

    Version of Record online : 4 JUN 2015, DOI: 10.1111/jdv.13198

  12. Omalizumab (Xolair): Anti-Immunoglobulin E Treatment in Allergic Diseases

    Handbook of Therapeutic Antibodies

    Claus Kroegel, Martin Foerster, Pages: 951–997, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch37

  13. Omalizumab may not inhibit mast cell and basophil activation in vitro

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1832–1836, J. Gericke, T. Ohanyan, M.K. Church, M. Maurer and M. Metz

    Version of Record online : 26 SEP 2014, DOI: 10.1111/jdv.12693

  14. You have free access to this content
    Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria

    Allergy

    Volume 72, Issue 4, April 2017, Pages: 519–533, A. P. Kaplan, A. M. Giménez-Arnau and S. S. Saini

    Version of Record online : 4 JAN 2017, DOI: 10.1111/all.13083

  15. You have full text access to this OnlineOpen article
    Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

    Clinical & Experimental Allergy

    Volume 44, Issue 11, November 2014, Pages: 1371–1385, J. P. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. E. Owen, I. Jones and P. J. Lowe

    Version of Record online : 21 OCT 2014, DOI: 10.1111/cea.12400

  16. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

    Allergy

    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Version of Record online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  17. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients

    Pediatric Pulmonology

    Volume 52, Issue 2, February 2017, Pages: 190–197, Raphaële Nové-Josserand, Soazic Grard, Lila Auzou, Philippe Reix, Marlène Murris-Espin, François Brémont, Benyebka Mammar, Laurent Mely, Dominique Hubert, Isabelle Durieu and Pierre-Régis Burgel

    Version of Record online : 7 OCT 2016, DOI: 10.1002/ppul.23612

  18. Impact of omalizumab on medical cost of childhood asthma in Japan

    Pediatrics International

    Volume 58, Issue 5, May 2016, Pages: 425–428, Hideki Yoshikawa, Mihoko Iwata, Hiroshi Matsuzaki, Rintaro Ono, Yoko Murakami, Naohiko Taba, Satoshi Honjo, Chikako Motomura and Hiroshi Odajima

    Version of Record online : 13 MAY 2016, DOI: 10.1111/ped.12936

    Corrected by:

    Corrigendum: Corrigendum

    Vol. 59, Issue 2, 243, Version of Record online: 17 FEB 2017

  19. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Version of Record online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  20. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x